| HIV Infections
Prezcobix vs Prezista
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Prezcobix vs Prezista with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrezista has a higher rate of injection site reactions vs Prezcobix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Prezista but not Prezcobix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Prezcobix
Prezista
At A Glance
Oral
Once daily
HIV-1 protease inhibitor
Oral
Once daily or Twice daily
HIV-1 protease inhibitor
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections Adults and pediatric patients >=40 kg: 800 mg/150 mg once daily with food; pediatric patients 25 kg to <40 kg: 675 mg/150 mg once daily with food; pediatric patients 3 years and older, 15 kg to <25 kg: 600 mg/90 mg tablet for oral suspension dispersed in water, once daily with food.
HIV-1 Infections (treatment-naive adults) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, no darunavir resistance) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, at least one darunavir resistance substitution) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pregnant patients) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pediatric patients, 3 to less than 18 years) Weight-based dosing with ritonavir, oral, with food. Dosage based on body weight and resistance status, not to exceed adult dose
Contraindications
- Co-administration with alfuzosin
- Co-administration with carbamazepine, phenobarbital, or phenytoin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin or simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil when used for pulmonary arterial hypertension
- Co-administration with orally administered midazolam or triazolam
- Co-administration with alfuzosin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin
- Co-administration with simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil for pulmonary arterial hypertension
- Co-administration with orally administered midazolam
- Co-administration with triazolam
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, rash, headache, abdominal pain, vomiting
Postmarketing Redistribution of body fat, rhabdomyolysis (with HMG-CoA reductase inhibitors), crystal nephropathy, crystalluria, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms
Most common (>=5%, treatment-naive) Diarrhea, headache, abdominal pain, rash, nausea, vomiting
Most common (>=5%, treatment-experienced) Diarrhea, nausea, rash, abdominal pain, vomiting
Serious Hepatotoxicity, severe skin reactions (Stevens-Johnson Syndrome, toxic epidermal necrolysis), acute pancreatitis, diabetes mellitus, hyperglycemia, immune reconstitution syndrome
Postmarketing Rhabdomyolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, crystal nephropathy, crystalluria
Pharmacology
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles; cobicistat is a mechanism-based CYP3A inhibitor that increases darunavir systemic exposure without intrinsic antiviral activity.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Prezcobix
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (1/12) · Qty limit (11/12)
Prezista
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Prezcobix
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Prezista
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Prezcobix
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Prezista
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PrezcobixView full Prezcobix profile
PrezistaView full Prezista profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.